TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

Amgen Inc (AMGN) reports a 23% revenue increase, driven by strong product sales and promising developments in its innovative ...

My name is Julianne, and I will be your conference facilitator today for Amgen's third-quarter 2024 financial results conference call. (Operator Instructions) I would now like to introduce Justin ...

Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $383.00.

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.

It has some rivals in its push to the IgG4-RD market, notably Amgen which reported positive topline results from a phase 3 trial of its CD19-directed antibody Uplizna (inebilizumab), acquired as ...

Amgen AMGN reported third-quarter 2024 adjusted earnings of $5.58 per share, which beat the Zacks Consensus Estimate of $5.11 ...